Fol­low­ing pro­gram cuts and amid drug launch, Roivant lines up $1B shelf reg­is­tra­tion

Roivant Sci­ences had about $2 bil­lion at the end of June. But the re­peat vant-mak­er wants the op­tion to se­cure more mon­ey for its ap­pa­ra­tus, ac­cord­ing to pa­per­work with the SEC.

A shelf reg­is­tra­tion state­ment with mul­ti­ple prospec­tus­es, in­clud­ing a sales agree­ment via the help of Cowen, was filed with the agency on Mon­day. Roivant is of­fer­ing up a to­tal of $1 bil­lion.

Roivant cur­rent­ly has no plans to use the po­ten­tial pro­ceeds, a spokesper­son tells End­points News via email. “We did it now be­cause un­der se­cu­ri­ties law we weren’t al­lowed to have a shelf un­til this month be­cause of when we went pub­lic,” the spokesper­son wrote. Roivant land­ed on the Nas­daq last year in a high­ly watched SPAC merg­er that gave the com­bined com­pa­ny a $7.3 bil­lion val­u­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER